• Asthma

  • Eczema

  • Food Allergies

  • Hay Fever

Components of the human gut microbiome confer immunity against various diseases.

HpVac's new molecule HpVac-R13 harnesses the beneficial potential of gastric bacteria

A revolution in the first-line treatment of allergic diseases is under way

 

HpVac Appoints Joana Vitte, MD, PhD, as Chief Scientific Officer



Significant expansion of allergy research expertise

 

Geneva, Switzerland, November 23, 2022 – HpVac SA, a company developing novel preventive and therapeutic first-line therapies against allergic and inflammatory diseases, today announced that Joana Vitte, MD, PhD, Habil. will be joining HpVac as Chief Scientific Officer.

 

Joana Vitte is an experienced scientist with a strong track record in allergy diagnostics and clinical research. She brings significant knowledge in human immunology, flow cytometry, and allergy testing. Among others, her work focuses on the interplay of allergic and anti-infectious immune responses. Joana Vitte has a joint position as Associate Professor of Immunology at Aix-Marseille University and the University Hospital of Marseille and is also Associate Researcher at the Institut d'Épidémiologie et de Santé Publique (IDESP) of the University of Montpellier. She is also Vice President for science and education at the French Society of Allergology.

 

"We warmly welcome Joana Vitte as our new Chief Scientific Officer," said Dr. Jeffrey Shaw, CEO of HpVac. "Her research expertise in allergology and immunology will be very valuable for further strengthening our pipeline and for progressing our lead compound HpVac-R13 into clinical development."

 

"I very much look forward to working with the team at HpVac," said Joana Vitte. "I am convinced that the Company has discovered a key component of microbiome-based immune modulation that plays a central role in the development of allergic diseases. I am therefore excited to help advance this novel therapeutic approach through preclinical and clinical stages."

 

HpVac´s therapeutic concept is based on the observation that certain components of the human gut microbiome confer protection against various diseases. The Company´s lead compound HpVac-R13 is a molecule harnessing the beneficial potential of some microbial species. The compound is a patented, recombinant version of a naturally occurring immunomodulatory protein and is associated with strong epidemiological evidence of protecting humans against asthma and other allergic diseases.

Previous announcements

HpVac Announces New Animal Data of its Lead Compound Demonstrating Protection Against Allergic Asthma

 

Major milestone for accelerating the development of HpVac-13 in allergic diseases

 

Geneva, Switzerland, October 17, 2022 – HpVac SA, a company developing novel preventive and therapeutic first-line therapies against allergic and inflammatory diseases, today announced novel data on its lead compound HpVac-13 for the treatment and prevention of asthmatic attacks in an animal disease model of allergic asthma.

 

Based on the observation that certain components of the human gut microbiome confer protection against various diseases, HpVac has developed HpVac-13, a molecule harnessing the beneficial potential of some microbial species. The compound is a patented, recombinant version of a naturally occurring immunomodulatory protein and demonstrates strong epidemiological evidence of protecting humans against asthma and other allergic diseases.

 

The Company now disclosed the results of testing the compound in a common animal disease model of allergic asthma. Mice sensitized intranasally with whole-body house dust mite extract – a procedure which has been shown to reproduce hallmarks of human allergic asthma, including Th2-driven allergic inflammation and pronounced airway hyperresponsiveness – were treated with HpVac-13 and subsequently challenged with the antigen. As compared to untreated controls, treated mice demonstrated a statistically significant reduction in airway hyperresponsiveness. In addition, a reduction in bronchoalveolar lavage total cell count (BAL TCC), including a reduction of recruitment of eosinophils into BAL, was observed. Eosinophils are involved in the development of severe asthma or asthma exacerbation and used as a biomarker for asthma. Moreover, treated mice showed a remarkable reduction in mucus-producing cells and an improvement of lung function through reduction in airway hyperresponsiveness.

 

"We are very pleased to have demonstrated that our compound significantly reduces asthma symptoms in this standard model," said Dr. Christine Serratrice, CMO of HpVac. "We also see a reduction in typical asthma biomarkers. All in all, HpVac-R13 displays anti-inflammatory properties associated with T-cell and B-cell activation and has a unique phenotypic profile which does not resemble any other known drug molecule."

 

"We strongly believe that our compound paves the way for a disease-modifying allergy treatment," said Dr. Jeffrey Shaw, CEO of HpVac. "With one capsule a week, we may be able to address a broad spectrum of allergic diseases without causing adverse side effects."

 

He added that the Company is initiating large-scale GMP production of its lead molecule and is in the process of starting IND-enabling studies.

HpVac-R13

HpVac is addressing one of the most significant unmet needs in human medicine: allergic diseases, in particular asthma, both in adults and in children


HpVac-R13 is an immunomodulatory protein with strong epidemiological evidence of activity in humans against asthma and other allergic diseases

Research

In the course of her award-winning studies, Prof. Dr. Anne Müller and her team at the University of Zurich have discovered that HpVac-R13 alone has a tolerogenic effect that confers protection against several allergic diseases